References
- Revlimid Product Monograph. Summit, NJ: Celgene Corporation. March 2018 Available from: https://media.celgene.com/content/uploads/sites/23/Revlimid-Product_Monograph_-_English_Version.pdf
- Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–3084.
- Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
- Moreau P. How I treat myeloma with new agents. Blood. 2017;130:1507–1513.
- McCarthy P, Holstein SA, Petrucci M, et al. Lenalidomide maintenance after autologous stem cell transplant in newly diagnosed multiple myeloma. A meta-analysis. JCO. 2017;35:3279–3289.
- Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13:424–429.
- Barley K, He W, Agarwal S, et al. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leukemia Lymphoma. 2016;57:2510–2515.
- Phillips J, Kujawa J, Davis-Lorron M, et al. Successful desensitization in a patient with lenalidomide hypersensitivity. Am J Hematol. 2007;82:1030.
- Seki J, Banglawala S, Lentz E, et al. Desensitization to lenalidomide in a patient with relapsed multiple myeloma. Clin Lymph Myel Leuk. 2013;13:162–165.
- Seki J, Sakurai N, Kukreti V. Lenalidomide desensitization in systemic light-chain amyloidosis with multi-organ involvement. J Clin Med Res. 2015;7:807–811.
- Lee M, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167:127–146.
- Penna G, Allegra A, Romeo G, etal. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQBB1*0602. Acta Oncol. 2012;51:944–947.
- Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immun. 2013;62:313–325.
- Scherer K, Brockow K, Aberer W, Gooi J, et al. Desensitization in delayed drug hypersensitivity reactions - an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013;68:844–852.
- Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129:2359–2367.
- Tinsley S, Kurtin S, Ridgewa J. Practical management of lenalidomide-related rash. Clin Lymph Myel Leuk. 2015;S1: S65–S69.
- Pomalyst Product Monograph. Summit, NJ: Celgene Corporation. January 31 2018 Available from: https://media.celgene.com/content/uploads/sites/23/POMALYST_Product_Monograph_English_Version.pdf
- Seki JT, Sakurai N, Lam W, et al. Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents. Curr Oncol. 2017;24:328–e332.